PharmiWeb.com - Global Pharma News & Resources

Clinical research - Press Releases

Date Title Company
10-Jan-2024 Ariceum Therapeutics files for UK Clinical Trial Authorisation (CTA) to test its First-in-Class Iodine-123 labelled PARP inhibitor in patients with recurrent glioblastoma Ariceum Therapeutics
10-Jan-2024 AbbVie Launches PRODUODOPA® (foslevodopa/foscarbidopa) for People Living with Advanced Parkinson's Disease in the European Union AbbVie
09-Jan-2024 Velocity Clinical Research transforms patient experience and recruitment with VISION technology platform Velocity Clinical Research
09-Jan-2024 AMLo Biosciences publish pivotal data for diagnostic biomarker technology AMBLor® in identifying melanomas at low risk of metastasis AMLo Biosciences
09-Jan-2024 HighRun DataScience Propels Retail Businesses With Advanced Data Analytics HighRun DataScience
09-Jan-2024 CD Biosciences Announces Expanded Capabilities for Mechanistic Target of Rapamycin Research in Diabetes and Metabolism CD BioSciences
09-Jan-2024 CD Biosciences Launches Substrate-Chromogens for Immunohistochemistry CD Biosciences
09-Jan-2024 STEMart Launches New Force Degradation Services to Ensure Drug Stability and Safety STEMart
09-Jan-2024 CD Bioparticles Announces Expanded Offerings of Polydimethylsiloxane for Cutting-Edge Research CD Bioparticles
09-Jan-2024 CD Bioparticles Unveils Versatile Plain Polystyrene Particles for Diverse Bioresearch Applications CD Bioparticles
09-Jan-2024 Creative Diagnostics Launches New P53 and Tp53 Antibodies for Cancer Research Creative Diagnostics
09-Jan-2024 Creative Diagnostics Announces MDT Services for Measuring Antibacterial Effectiveness Creative Diagnostics
09-Jan-2024 Creative Diagnostics Launches Rapid Robenidine Test Reagents for the Analysis of Anticoccidial Residues Creative Diagnostics
08-Jan-2024 Cell and Gene Therapy Catapult announces successful renewal of its five-year funding from Innovate UK to further support the advanced therapies sector The Cell and Gene Therapy Catapult
05-Jan-2024 LAUSANNE, Switzerland, Jan. 04, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that it received a notice from the New York Stock Exchange (NYSE) on January 2, 2024 that the Company has regained compliance with the continued listing minimum price criteria set forth in Section 802.01C of the NYSE Listed Company Manual and, as a result, will be removed from the NYSE’s noncompliant issuers list. The Company previously received a notice from the NYSE that it was not in comp ADC Therapeutics
05-Jan-2024 selectION, Inc. to Present Update on Clinical Progress at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on January 11, 2024 selectION, Inc.
04-Jan-2024 PharmaKure granted MHRA Clinical Trial Authorisation (CTA) for PK051 for the treatment of mild cognitive impairment due to Alzheimer’s Disease PharmaKure
04-Jan-2024 Anocca Secures GMP Manufacturing License To Push Novel KRAS TCR-T Cell Therapies Into Clinical Development Anocca AB
04-Jan-2024 Vicore Confirms IPF Development Program on Track and Provides Early-Stage Pipeline Updates Vicore Pharma Holding AB
03-Jan-2024 AMLo Biosciences publish pivotal data for diagnostic biomarker technology AMBLor® in identifying melanomas at low risk of metastasis AMLo Biosciences